Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 83 ADR Reports from Patients Received in 4 Months after March Launch of New Reporting System: MHLW
November 20, 2019
- Regenerative Medicine Industry Calls for Appropriate Reward for Innovation: Public-Private Confab
November 19, 2019
- MHLW Panel to Discuss Eisai’s Insomnia Med and More on Nov. 29, Skips Ono’s Cachexia Drug Again
November 18, 2019
- Inpatient Generic Use Tops 80% in Japan Hospitals: Chuikyo
November 18, 2019
- 8.2% of Hospitals Have Formularies: Chuikyo Survey
November 18, 2019
- MHLW Orders Label Revisions for Xtandi, Erleada to Include Interstitial Lung Disease to ADR List
November 18, 2019
- Lower House OKs PMD Law Amendment Bill
November 15, 2019
- Will Japan Reinstate Sakigake Status for Aducanumab? Many See It Unlikely
November 15, 2019
- Only 2.4% of Pharmacies Have Generic Drug Formularies in Their Region: Tokyo Govt Survey
November 15, 2019
- PMD Law Amendment Bill Clears Lower House Health Panel
November 14, 2019
- Forteo, Enbrel Biosimilars OK’ed for Self-Injection; Evrenzo under Flat-Fee System
November 14, 2019
- Chuikyo Rep Calls for Modifying Re-Pricing Criteria with Eye to Xolair’s Pollen Allergy Use
November 14, 2019
- Panel OKs Orphan Status for 3 Cell, Gene Therapies
November 14, 2019
- Astellas’ HIF-PH Inhibitor, Trintellix, Venclexta, and Many More OK’ed for Listing on Nov. 19
November 13, 2019
- Keytruda to Get 17.5% Price Cut in February
November 13, 2019
- Bayer’s Xtandi Rival, AbbVie’s JAK Inhibitor Up for MHLW Panel Review on Nov. 25; 2 More Indications for Keytruda Also on Agenda
November 12, 2019
- Public-Private Confab Set for November 18; 2020 Reform, PMD Law Up for Discussion
November 12, 2019
- MHLW Sees No Major Problem with Current Rules for Low-Price Products, Chuikyo Questions Price Negotiation Process
November 12, 2019
- Keytruda Faces Price Slash on Better-than-Expected Sales
November 12, 2019
- PMDA Reviewing Safety Risks for Tecentriq, Tagrisso and More
November 12, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…